|
 The Central Drugs Standard Control Organization (CDSCO) has launched a series of digital initiatives aimed at revolutionizing the pharmaceutical regulatory framework in India. These initiatives, showcased at the iPHEX 2024 event, are designed to enhance transparency, improve efficiency, and ensure the highest standards of safety and quality in the pharmaceutical sector, stated Drugs Controller General of India (DCGI) Dr Rajeev Singh Raghuvanshi.
The three-day premier event started on August 28, 2024, at the IEML Knowledge Park-II, Greater Noida.
IPHEX 2024 is set to be a monumental event, representing the largest platform to showcase the entire Indian pharmaceutical spectrum to a global audience. Organized by Pharmexcil, this event promises to be a hub of innovation, collaboration, and industry insights.
“CDSCO digital initiatives include the National Single Window System (NSWS). The NSWS aims to provide a unified platform for all regulatory approvals at the national level, minimizing the need for multiple interfaces and ensuring a more streamlined process for the industry. While the system is currently partially implemented for medical devices and clinical trials, a phased rollout is planned for other licenses,” said Dr. Raghuvanshi.
He further informed that another big initiative is the Online National Drug License System (ONDLS). Branded as the "One Nation-One Drug Licensing System”, this initiative offers a digital portal managed by CDSCO for uniform drug licensing across all States and Union Territories. It standardizes requirements and interpretations, maintains a comprehensive database of licenses, and enables prompt verification, ensuring no discrepancies or anomalies in the licensing process.
Another big initiative is the Track and Trace System. This system is being introduced to ensure the traceability of active pharmaceutical ingredients (APIs) and top formulations. QR codes or barcodes will be used for all APIs imported or manufactured in the country, starting with the top 300 brands of formulations. Future phases will extend this to all remaining formulations, vaccines, and narcotic drugs.
“To facilitate faster decision-making, CDSCO has introduced streamlined Subject Expert Committee (SEC) meetings, allowing for more inclusive and efficient applicant presentations. This new approach aims for expedited disposals and includes a two-tier appeal mechanism for grievances,” Dr. Raghuvanshi explained.
Doorstep Delivery initiative will allow the sale and delivery of prescription drugs directly to consumers’ homes using registered emails. This measure is intended to increase convenience while maintaining robust regulatory oversight. SUGAM portal is a comprehensive digital platform that integrates all import-related processes, clinical trials, human and veterinary drugs, cosmetics, medical devices, and ethics committee approvals. The SUGAM portal supports all aspects of pharmaceutical regulation, ensuring compliance and ease of access to regulatory services.
These initiatives align with the Government of India's "Digital India" mission, focusing on empowering stakeholders with streamlined, transparent, and efficient regulatory systems. By implementing these digital measures, CDSCO aims to reinforce India's position as a global leader in pharmaceuticals, ensuring that quality and safety remain at the forefront of industry practices.
|